Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company ...
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused ...
Fourteen people fell sick in a Staphylococcus aureus outbreak in China after eating contaminated donkey and goose meat. In ...
WQRF Rockford on MSN
Skin infection alert issued for South Beloit High School students
South Beloit High School is notifying families after cases of a highly contagious skin infection were detected in several ...
Lakewood-Amedex Biotherapeutics Inc., a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, ...
Stocktwits on MSN
Armata Pharmaceuticals Stock Soars To Record High After Phage Therapy Data In Deadly Infection Trial; Retail Traders Pile In
The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus ...
Armata Pharmaceuticals ( ($ARMP) ) has issued an update. On October 22, 2025, Armata Pharmaceuticals announced positive results from its Phase 2a ...
Medpage Today on MSN
When Infection Forces Heart Device Removal, Shorter Antibiotic Course May Suffice
ATLANTA -- For patients with cardiovascular implantable electronic device (CIED)-associated infections, a shorter course of ...
Armata Pharmaceuticals (ARMP) stock soars 300% after the company announces promising Phase 2 trial results for its AP-SA02 antibacterial agent. Read more here.
An MIT team used artificial intelligence to design novel antibiotics, two of which showed promise against MRSA and gonorrhea.
Armata Pharmaceuticals said its experimental treatment for a serious bloodstream infection showed positive results in a recent mid-stage trial.
A 3-year-old girl who is in the maintenance phase of chemotherapy for leukemia is seen for a moderately painful rash on her ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback